Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo

Wells Fargo analyst Zachary Fadem raised the firm’s price target on Taysha Gene Therapies (TSHA) to $11 from $8 and keeps an Overweight rating on the shares. The firm sees another year of outperformance for the stock, driven by continued momentum in the company’s pivotal Rett syndrome study following last year’s alignment with FDA on a favorable design.